This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A vaccine vaccine may be in sight for coccidioidomycosis, the so-called San Joaquin fever or valley fever expected to afflict as many as 85,000 US residents this year.
The killed vaccine, prepared from the spherical multinucleated cells of Coccidioides immitis in the spherule or parasitic stage (when endospores develop), is about to undergo a large-scale, double-blind clinical trial. According to its developer, Hillel Benjamin Levine, PhD, the vaccine does not prevent infection but minimizes fungal replication in the lungs and prevents systemic spread.
At least 3,000 unpaid volunteers will be recruited for the trial. Half will receive the vaccine in three 1.75-mg intramuscular injections one week and six weeks apart. The rest will be given a saline solution.
Some 500 volunteers already have been recruited from an endemic area around Bakersfield, Calif, between Los Angeles and San Francisco. Additional persons will be selected from the Tucson, Ariz, area this month,
Coccidioidomycosis vaccine trial planned with 3,000 volunteers. JAMA. 1981;245(17):1711–1716. doi:10.1001/jama.1981.03310420003001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: